A Delaware jury has ruled in favor of Apple in a patent infringement case against Masimo, awarding Apple a symbolic $250 in damages. The jury found that Masimo infringed on Apple’s patents related to health technology in older smartwatch models, but current Masimo products were not found to infringe. This legal battle, which began in 2022, has been a point of contention between the two companies and highlights the competitive landscape in the wearables market.
Masimo (MASI) stock saw a significant jump following the election of new board members, but investors need to consider whether the recent gains can be sustained. The stock’s performance will be closely tied to the company’s upcoming earnings report and any changes in analyst sentiment.
The highly anticipated Apple Watch Series 10 has been released, but U.S. users are facing a major setback: the absence of blood oxygen tracking. This feature, introduced with the Apple Watch Series 6, has been temporarily banned due to a patent dispute with medical tech company Masimo. The legal battle centers around Apple’s use of blood oxygen sensor technology, which Masimo claims infringes on its patents. While Apple has challenged the ruling, the future of blood oxygen tracking on the Apple Watch Series 10 in the US remains uncertain.
